AstraZeneca, which received approval for Olaparib in 2018 ... been directed to withdraw the said indication and revise the package insert" the DCGI said in a letter, which was reviewed by Mint.
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...
Hosted on MSN2mon
NHS use of new breast cancer drug given green lightPatients with a form of breast cancer in England will be offered a new treatment after it was given the green light for NHS use. Olaparib will offer the chance of ‘longer, healthier lives’ for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results